NCT04309578 2024-02-28
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Phase 2 Unknown
Clinical Trials
43 trialsNCT05237349 2024-01-05
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT06047860 2023-09-21
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05790447 2023-03-30
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04985721 2023-03-15
IMPARP-HRD
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT04225767 2022-12-13
CaEP-R
Zealand University Hospital
Phase 2 Unknown
NCT02461849 2022-06-15
Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy
Samsung Medical Center
Phase 2 Unknown
NCT02366884 2022-04-06
Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)
Dr. Frank Arguello Cancer Clinic
Phase 2 Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT05241132 2022-02-15
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT05115500 2021-11-10
ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04547829 2021-09-02
Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy
Sun Yat-sen University
Phase 2 Unknown
NCT03564548 2021-07-28
REBORN
Tetra Bio-Pharma
Phase 2 Unknown
NCT04780854 2021-07-28
Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)
Cairo University
Phase 2 Unknown
NCT02795650 2021-02-26
AVATAR
Hospital Universitario de Fuenlabrada
Phase 2 Unknown
NCT04761744 2021-02-21
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
Korean Cancer Study Group
Phase 2 Unknown
NCT02029937 2021-01-14
High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia
Anandasabapathy, Sharmila, M.D.
Phase 2 Unknown
NCT04710472 2021-01-14
MentorA1
Associacao de Investigacao de Cuidados de Suporte em Oncologia
Phase 2 Unknown
NCT04695223 2021-01-06
Arsenic Trioxide for Structural p53 Mutations
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT04698213 2021-01-06
TIDE-A
Consorzio Oncotech
Phase 2 Unknown
NCT03113266 2020-09-30
Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Unknown
NCT04533321 2020-08-31
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
National University Hospital, Singapore
Phase 2 Unknown
NCT04131621 2020-04-15
CheCUP
University Hospital Heidelberg
Phase 2 Unknown
NCT03864575 2019-07-12
NICE-COMBO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT03693326 2018-10-03
PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities
Asan Medical Center
Phase 2 Unknown
NCT03693339 2018-10-03
Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation
Asan Medical Center
Phase 2 Unknown
NCT03588533 2018-07-17
HERZUMA-GC
Dong-A University Hospital
Phase 2 Unknown
NCT03543306 2018-06-01
Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation
Asan Medical Center
Phase 2 Unknown
NCT03341286 2017-11-14
TK3bFIIABC
Faculdade de Medicina do ABC
Phase 2 Unknown
NCT03158324 2017-06-15
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077
National University Hospital, Singapore
Phase 2 Unknown
NCT02674646 2016-02-04
ROSETTA
Technical University of Munich
Phase 2 Unknown
NCT01232374 2015-08-20
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
Biotech Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT00943137 2015-06-19
The Optimization of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer
National University Hospital, Singapore
Phase 2 Unknown
NCT02400866 2015-03-27
A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy
Korean South West Oncology Group
Phase 2 Unknown
NCT02340845 2015-01-19
Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans
Oeyama-Moto Cancer Research Foundation
Phase 2 Unknown
NCT01154270 2013-04-24
COSMIC
Heidelberg University
Phase 2 Unknown
NCT00751894 2011-01-19
MEG-5
University Hospital, Clermont-Ferrand
Phase 2 Unknown
NCT01129154 2010-08-30
PASCE
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT00411853 2009-07-31
Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients
Sheba Medical Center
Phase 2 Unknown
NCT00894569 2009-05-14
PACET-CUP
Heidelberg University
Phase 2 Unknown
NCT00781209 2008-10-28
The Role of Posterior Fossa Irradiation (PFI) Plus Stereotactic Radiosurgery (SRS) for Cerebellar Metastases
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
NCT00521287 2008-03-03
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
Mackay Memorial Hospital
Phase 2 Unknown
NCT00149006 2007-03-14
Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors
Hadassah Medical Organization
Phase 2 Unknown